PFG Investments LLC Invests $465,000 in Balchem Co. (NASDAQ:BCPC)

PFG Investments LLC acquired a new position in shares of Balchem Co. (NASDAQ:BCPC) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 3,000 shares of the basic materials company’s stock, valued at approximately $465,000.

Several other large investors have also modified their holdings of BCPC. Signaturefd LLC lifted its holdings in shares of Balchem by 123.0% in the fourth quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock valued at $25,000 after purchasing an additional 91 shares in the last quarter. Principal Securities Inc. purchased a new stake in shares of Balchem in the fourth quarter valued at $28,000. Operose Advisors LLC purchased a new stake in shares of Balchem in the third quarter valued at $31,000. GAMMA Investing LLC purchased a new stake in shares of Balchem in the fourth quarter valued at $56,000. Finally, Allworth Financial LP lifted its holdings in shares of Balchem by 17.8% in the fourth quarter. Allworth Financial LP now owns 953 shares of the basic materials company’s stock valued at $142,000 after purchasing an additional 144 shares in the last quarter. 87.91% of the stock is owned by institutional investors.

Balchem Stock Up 1.5 %

Shares of NASDAQ:BCPC traded up $2.15 during midday trading on Tuesday, hitting $141.38. 166,356 shares of the stock were exchanged, compared to its average volume of 104,380. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.38 and a current ratio of 2.12. Balchem Co. has a 52-week low of $110.74 and a 52-week high of $159.52. The business’s fifty day simple moving average is $151.53 and its two-hundred day simple moving average is $140.35. The company has a market capitalization of $4.56 billion, a PE ratio of 42.20, a P/E/G ratio of 3.09 and a beta of 0.71.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings data on Friday, February 16th. The basic materials company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.02. Balchem had a return on equity of 10.69% and a net margin of 11.77%. The business had revenue of $228.70 million during the quarter, compared to analyst estimates of $234.66 million. During the same period last year, the company earned $0.66 earnings per share. Balchem’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, research analysts predict that Balchem Co. will post 4.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered Balchem from a “buy” rating to a “hold” rating in a report on Thursday, April 25th.

Insider Buying and Selling at Balchem

In other Balchem news, CAO William A. Backus sold 9,180 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $156.37, for a total transaction of $1,435,476.60. Following the transaction, the chief accounting officer now directly owns 12,914 shares in the company, valued at $2,019,362.18. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Balchem news, CAO William A. Backus sold 9,180 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $156.37, for a total transaction of $1,435,476.60. Following the transaction, the chief accounting officer now directly owns 12,914 shares in the company, valued at $2,019,362.18. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO William A. Backus sold 15,000 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $154.73, for a total value of $2,320,950.00. Following the transaction, the chief accounting officer now directly owns 12,914 shares of the company’s stock, valued at approximately $1,998,183.22. The disclosure for this sale can be found here. Insiders have sold a total of 76,630 shares of company stock worth $11,843,249 over the last three months. Corporate insiders own 1.77% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.